MyChart is not for medical emergencies. If you have a medical emergency, call 911.
If you need help with MyChart, call us at 1-844-442-4278.
The Center for Liver Diseases at the University of Chicago Medicine offers leading-edge approaches for diagnosing and treating the full range of chronic and acute liver diseases in adults. In addition to receiving the most effective therapies, patients here receive personalized support and patient education to help them cope with long-term illness and treatment. Michael Charlton, MBBS, — a world-renowned specialist in liver care — leads our team of hepatologists and co-directs the Transplant Institute.
Our hepatology program targets a broad spectrum of liver-related diseases. Our hepatologists have expertise in the following liver diseases and more.
Specialists at the Center for Liver Diseases use an array of advanced diagnostic methods to zero in on the cause of an individual’s liver disorder and determine the degree of severity.
The Metabolic and Fatty Liver program brings together liver disease experts from multiple specialties to ensure our patients with non-alcoholic liver disease and non-alcoholic steatohepatitis receive comprehensive care.
Our liver tumor team has expertise in both end-stage liver disease and liver cancer, including primary and metastatic disease. We manage complex cases and treat patients without curative options.
Our internationally renowned specialists have extensive expertise in treating common and complex liver diseases.
Some people with liver disease have related medical problems in other areas, such as diabetes, kidney disease or heart disease. At UChicago Medicine, all of our highly specialized physicians work under the same roof and are in continual communication with one another. Whether you need care from an endocrinologist, nephrologist, cardiologist, transplant surgeon or any other specialist, you can be assured that these specialists will collaborate on your behalf.
Individually tailored treatment, personalized support and ongoing education help patients through the lengthy and often challenging journey of living with liver disease. Nurse specialists, physician assistants, social workers, registered dietitians and other members of our team have important roles supporting each patient and their family throughout treatment.
Today’s UChicago Medicine physicians, researchers and members of our hepatology team build on more than eight decades of experience, discoveries and treatment innovations related to liver disease. Our team oversees many clinical trials of new therapies for liver disease.
Research leads to better ways to treat, diagnose and even prevent liver disease. Members of our team are actively involved in research on two fronts: in the lab (basic research) and with patients (clinical research).
In the lab, scientists are focusing on hepatitis and other liver diseases at the cellular level. Deeper understanding about how liver disease develops and progresses can lead to more effective treatments.
Clinical research often has a more timely impact on treating liver disease. As one of the nation’s leading academic hospitals, UChicago Medicine offers many clinical trials for promising new therapies. Often, these clinical trials are open to individuals whose disease has relapsed or resisted standard treatments.
The University of Chicago Medicine is one of the most experienced centers for liver transplantation. Our liver transplant program was established in 1984 — the first in the Midwest and only the fourth liver transplant program in the U.S. at that time. Over the decades, transplant surgeons here have made innovations that have revolutionized liver transplantation, particularly in the area of living-donor transplant.
The University of Chicago Medicine has one of the premier gastroenterology and hepatology programs in the United States. Year after year, our GI program is ranked among the nation’s best for treating digestive system disorders.
Brad Goodman knew he had a long wait for a new liver. For years, Brad was fighting off bile duct infections caused by primary sclerosing cholangitis. However, due to a breakthrough hepatitis C treatment, Brad received an organ that would probably have gone to someone much higher on the transplant listRead Brad's Story